Eton Pharmaceuticals, Inc. (ETON)

Market Cap	82.35M
Revenue (ttm)	32.64M
Net Income (ttm)	-936,000
Shares Out	25.65M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	12.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,974
Open	3.240
Previous Close	3.280
Day's Range	3.190 - 3.300
52-Week Range	2.420 - 5.810
Beta	1.18
Analysts	Strong Buy
Price Target	10.00 (+211.53%)
Earnings Date	May 9, 2024

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortison...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON

Financial Performance

In 2023, ETON's revenue was $32.64 million, an increase of 42.60% compared to the previous year's $22.89 million. Losses were -$936,000, -89.62% less than in 2022.

Analyst Forecast

According to one analyst, the rating for ETON stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(211.53% upside)

Analyst Consensus: Strong Buy